Feasibility of a Multi-omics Platform for Hematological Malignancies

What this Trial Is About

Researchers are investigating a wide range of hematological malignancies, including acute and chronic leukemias, myeloproliferative and lymphoproliferative disorders, and myelodysplastic conditions, as classified in the WHO 2022 guidelines. This collaborative biological study involves multiple Italian hematology centers and aims to explore disease characteristics and potential biomarkers using advanced multi-omics techniques. Both retrospective and prospective samples will be analyzed to better understand these blood cancers and related disorders. The study involves collecting bone marrow or peripheral blood samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids like cerebrospinal fluid and pathological pleural effusion from patients during routine diagnostic or relapse evaluations. Retrospective patients with previously stored frozen samples will also be included. Multi-omics analyses such as next-generation sequencing, bulk and single-cell transcriptomics, and phosphoproteomics will be performed, alongside functional drug testing on cultured malignant cells exposed to a library of 300 drugs at various concentrations over 72 hours. Participants will provide biological samples either retrospectively or prospectively during their regular diagnostic workups. These samples will be sent fresh or frozen to the central laboratory for detailed molecular and functional testing. The study will measure multi-omics features to identify disease biomarkers and assess the anti-cancer activity of bioactive compounds for personalized pharmacotyping. The research team will monitor these outcomes at baseline. The study is planned to continue until March 2030, with patient involvement focused on sample collection and laboratory analyses without altering standard care.

Feasibility of a Multi-omics Platform for Hematological Malignancies